Discovery Café Sessions
Monday, April 8th, 2019, 11:45 am - 1:00 pm
Applying AI to Save Lives During the Opioid Crisis
The U.S. is in the throes of a devastating epidemic of opioid addiction and overdose — some 130 people die nationally every day from opioids, says the National Institute on Drug Abuse. With a total economic cost of more than $78 billion a year, AI is being harnessed to develop new tools that can help alleviate this national crisis. This session will discuss AI-based strategies that academic and industry teams are leveraging to help clinical and public health officials better predict, identify, and treat opioid addiction, and also data privacy concerns.
Moderator: Thomas Sequist, MD, Chief Quality & Safety Officer, PHS
Bob Burgin, CEO, Amplifire Healthcare Alliance
Carm Huntress, CEO, RxRevu Inc
Sarah Wakeman, MD, Medical Director, Substance Use Disorder Initiative, MGH; Assistant Professor, Medicine, HMS
Scott Weiner, MD, Director, Brigham Comprehensive Opioid Response and Education (B-CORE) Program, BH; Assistant Professor, HMS
Community Hospitals: Key Component in Healthcare Transformation
Community hospitals are the largest sources of patient care in the U.S. As such, they represent a frontier in the transformation of health care. How are these organizations using AI and digital technologies to drive transformation? What are the distinctions from academic medical centers? This session will address these and other topics that impact community hospitals.
Moderator: Michael Jaff, DO, President, NWH, PHS, Professor of Medicine, HMS
Fabien Beckers, PhD, CEO, Arterys
Joanna Geisinger, CEO, TORq Interface
John Miller, MD, Director, Retinal Imaging, MEE; Assistant Professor, Ophthalmology, HMS
Lee Schwamm, MD, Director, Center for TeleHealth and Exec Vice Chair, Neurology, MGH; Professor, Neurology, HMS
Tal Wenderow, CEO, Beyond Verbal
Digital Management of Diabetes
Across the spectrum of patient care, the management of diabetes has been flooded with new technology and treatment options for both type 1 and type 2 diabetes – there is a range of new devices and software, including automatic insulin infusion systems, glucose sensors, AI-based algorithms and decision support tools, with an artificial pancreas on the horizon. This session will focus on these areas and clinical use cases that highlight the value of AI.
Moderator: Deborah Wexler, MD, Clinical Director, Diabetes Center, MGH; Associate Professor, HMS
Marie McDonnell, MD, Section Chief and Director, Diabetes Program, BH; Lecturer, HMS
Michael Meissner, PhD, CTO and VP, MED, Sanofi
Joshua Riff, MD, CEO, Onduo
Marie Schiller, VP, Connected Care and Insulins Product Development and Site Head, Cambridge Innovation Center, Eli Lilly
AI and Its Impact on the Future of Emergency Care
There are over 136 million Emergency Department visits annually in the U.S. providing 24/7 unscheduled treatment for problems from minor illness to life threatening traumatic injuries. Emergency department care teams provide high quality, safe care in an efficient fashion. In this session, we consider the future of AI in emergency care from the initial decision to seek emergency care, to diagnostic processes within the ED and final disposition decision.. From chat bots for patient triage, telehealth for patient visits to machine learning outcome prediction, we will consider how these novel technologies will impact emergency care delivery.
Moderator: Adam Landman, MD, VP and CIO, BH; Associate Professor of Emergency Medicine, HMS
Peter Chai, MD, Assistant Professor, Emergency Medicine, BH, HMS
Emily Hayden, MD, Attending Physician, Emergency Medicine, MGH; Instructor, Surgery, HMS
Kohei Hasegawa, MD, Attending Physician, Emergency Medicine, MGH; Associate Professor, Emergency Medicine, HMS
Sean Kelly, MD, CMO, Imprivata; Assistant Professor, Emergency Medicine, HMS
Bijoy Sagar, VP, Chief Digital Technology Officer, Stryker
Mental Health, Smartphone Apps and the Promise of AI
Patients can face significant barriers when it comes to accessing high-quality, evidence-based treatment for mental illness. AI-enabled technologies, including smartphone-based tools, that may help close this treatment gap for patients worldwide. This session will focus on efforts to develop smartphone apps and other tools, including those designed to help predict patients’ moods and provide cognitive behavioral therapy.
Moderator: Sabine Wilhelm, PhD, Chief of Psychology; Director, OCD and Related Disorders Program, MGH; Professor, Psychology, HMS
Jennifer Gentile, PsyD, SVP, US Clinical Operations, Ieso Digital Health
Thomas McCoy, MD, Director of Research, Center for Quantitative Health, MGH; Assistant Professor, Psychiatry and Medicine, HMS
Christopher Molaro, CEO, Neuroflow
David Silbersweig, MD, Chairman, Department of Psychiatry, BH; Stanley Cobb Professor of Psychiatry, HMS
Jeremy Sohn, VP, Global Head of Digital Business Development and Licensing , Novartis
From Startup to Impact (Pharma and Diagnostics)
This session will introduce you to five leading start-up companies who will each share their respective impact in the pharmaceutical and diagnostic realms in 10-minute pitches.
Moderator: James Brink, MD, Radiologist-in-Chief, MGH; Juan M. Taveras Professor of Radiology, HMS
Moderator: James Nicholls, Managing Director, Fitzroy Health
Sarah Beeby, EVP, GM Lifesciences, Clinithink
Charles Cadieu, PhD, CEO, Bay Labs
JB Michel, PhD, SVP Data Science & GM USA, BenevolentAI
Art Papier, MD, CEO, VisualDx
Alex Zhavoronkov, PhD, CEO, Insilico Medicine, Inc